Stockwinners Market Radar for October 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Bristol Myers Squibb (BMY) and Mirati Therapeutics (MRTX) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8B. Mirati stockholders will also receive one non-tradeable Contingent Value Right for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1B of value opportunity. The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors. 2. Birkenstock (BIRK) has secured enough commitments from investors to price its U.S. initial public offering at the top of its indicated range and attain a $10B valuation, Reuters' Anirban Sen reports, citing people familiar with the matter. The German premium footwear company will make a final decision on pricing its IPO at the top of its $44-to-$49-per-share range on Tuesday, ahead of its shares debuting in New York on Wednesday, the sources said. 3. U.S. automaker Tesla (TSLA) sold 74,073 China-made electric vehicles in September, a 10.9% decrease from a year earlier, showed data from the China Passenger Car Association on Sunday, Reuters reports. Sales of China-made Model 3 and Model Y cars were down 12.0% from a month earlier. 4. Booking Holdings (BKNG) makes investing in travel easy, Jacob Sonenshine writes in this week's edition of Barron's. hares of the travel website have been the closest thing to a sure thing in the travel universe, outperforming airline stocks, hotels, and Expedia Group (EXPE) in recent years. Over the past three years, the stock has doubled the return of the S&P 500, with those gains having been driven by strength in the overall travel market and Booking's ability to turn that into profits, the author notes. Travel is getting trickier after the post-COVID boom, but Booking's strengths, particularly in Europe, give it an advantage that should mean continued outperformance in the years ahead, the publication adds. 5. Comcast (CMCSA) subsidiary Universal's "The Exorcist: Believer" placed first place at the domestic box office with a $27.2M debut, which was below expectations. Overseas, the horror pic earned an estimated $17.9M for a global start of $45.1M. "Believer" decided to move up its release by one week after superstar Taylor Swift announced that her new "The Eras Tour" movie would open on October 12. The singer's movie is tracking for a mega domestic debut in the $100M-$125M range.

09:27 EDT Ionis announces new results from analysis of exploratory cardiac endpoints - Ionis Pharmaceuticals (IONS) announced new results from a 66-week analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen, an investigational treatment for hereditary transthyretin-mediated amyloid polyneuropathy. In a pre-defined cardiac subpopulation of ATTRv-PN patients, treatment with eplontersen showed stabilization or improvement in cardiac function and structure relative to external placebo, including levels of N-terminal prohormone of brain natriuretic peptide, a measure of cardiac stress, and a trend towards improvement in echocardiographic parameters. The results were presented during a rapid-fire oral session at the 2023 Heart Failure Society of America Annual Scientific Meeting. Transthyretin-mediated amyloid cardiomyopathy is a systemic, progressive and fatal condition that typically leads to progressive heart failure and often death within three-to-five years from disease onset. Data from the study are expected as early as the first half of 2025. As part of a global development and commercialization agreement, Ionis and AstraZeneca (AZN) are seeking regulatory approval for eplontersen for the treatment of ATTRv-PN in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. This agreement was recently expanded to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America and all other countries outside the US. Eplontersen was granted Orphan Drug Designation in the U.S. for the treatment of transthyretin-mediated amyloidosis. The U.S. Food and Drug Administration granted a PDUFA action date of Dec. 22, 2023.

06:24 EDT Avidity Biosciences announces AOC 1001 data from MARINA trial, MARINA-OLE study - Avidity Biosciences announced new AOC 1001 data demonstrating improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1. AOC 1001, Avidity's lead clinical program utilizing its AOC platform, is designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. The AOC 1001 data from the Phase 1/2 MARINA trial and MARINA open-label extension study will be highlighted in an oral presentation at the 28th Annual Congress of the World Muscle Society in Charleston, South Carolina and can be found on Avidity's website on the Publications page. The new AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting previously reported positive data showing improvements in myotonia, muscle strength and mobility. With new long-term safety data from over 200 infusions totaling 46.2 patient-years of exposure, AOC 1001 continues to demonstrate favorable safety and tolerability with most adverse events mild to moderate. In May 2023, the U.S. Food and Drug Administration eased the partial clinical hold on AOC 1001, allowing Avidity to double the number of participants in the MARINA-OLE study receiving 4 mg/kg of AOC 1001 from 12 to 24 participants. Data from the 12 participants dose-escalated from 2 mg/kg to 4 mg/kg of AOC 1001 as part of the easement of the partial clinical hold showed no neurological events and no MRI changes following dosing. The company continues to work as quickly as possible to resolve the partial clinical hold. New AOC 1001 data demonstrate improvement in additional functional measures augmenting previously reported positive data that demonstrated improvements in functional assessments of myotonia, strength and mobility.